At the time of writing, Cardiff Oncology Inc [CRDF] stock is trading at $2.90, up 3.94%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRDF shares have gain 10.27% over the last week, with a monthly amount glided 14.62%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on September 06, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $8. On December 08, 2021, Robert W. Baird initiated with a Outperform rating and assigned a price target of $19 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $27 as its price target on October 22, 2020. Piper Sandler started tracking with a Overweight rating for this stock on October 08, 2020, and assigned it a price target of $25.
For the past year, the stock price of Cardiff Oncology Inc fluctuated between $0.94 and $6.42. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $2.90 at the most recent close of the market.
Analyzing the CRDF fundamentals
According to Cardiff Oncology Inc [NASDAQ:CRDF], the company’s sales were 0.67M for trailing twelve months, which represents an 50.93% jump. Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at -67.11%, Pretax Profit Margin comes in at -61.44%, and Net Profit Margin reading is -61.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -0.63 and Total Capital is -0.83. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.73 points at the first support level, and at 2.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.15, and for the 2nd resistance point, it is at 3.41.
Ratios To Look Out For
It is important to note that Cardiff Oncology Inc [NASDAQ:CRDF] has a current ratio of 4.97. In addition, the Quick Ratio stands at 4.97 and the Cash Ratio stands at 2.04. Considering the valuation of this stock, the price to sales ratio is 201.49, the price to book ratio is 2.52.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Dec 19 ’23 when 30000.0 shares were purchased.
